RESUMEN
Our objective is to determine the effectiveness of a therapeutic regimen for helicobacter pylori that includes a proton pump inhibitor, doxycycline, furazolidone and bismuth in our location. We carried out a retrospective study, non-randomized, in a private hospital in Lima, Peru. Patients with biopsy and/or rapid urease test proven helicobacter pylori infection after an endoscopy, from January 2017 to October 2022 were included. They received the therapeutic regimen of the study or an alternative triple regimen with a proton pump inhibitor, amoxicillin and levofloxacin and were followed with a urea breath test within 1 to 6 months upon completion of therapy. The quadruple therapy with furazolidone obtained success in 117/122 cases (95.9%) while the triple therapy with levofloxacin only in 5/16 (31.2%) when used for 7 days and 22/38 (57.9%) when used for 10 days, a statistically significant difference with p<0.001. Conclusion: Quadruple therapy with furazolidone reached high effectiveness in our location, while triple therapy with levofloxacin was not an acceptable alternative.
Asunto(s)
Infecciones por Helicobacter , Helicobacter pylori , Humanos , Bismuto/uso terapéutico , Doxiciclina/uso terapéutico , Inhibidores de la Bomba de Protones/uso terapéutico , Infecciones por Helicobacter/tratamiento farmacológico , Furazolidona/uso terapéutico , Furazolidona/farmacología , Antibacterianos/uso terapéutico , Levofloxacino/uso terapéutico , Levofloxacino/farmacología , Estudios Retrospectivos , Quimioterapia Combinada , Amoxicilina/uso terapéutico , Resultado del TratamientoRESUMEN
Nuestro objetivo es determinar si el tratamiento para Helicobacter pylori (HP) con doxiciclina, furazolidona, bismuto y un inhibidor de bomba de protones mantiene su efectividad en nuestra población. Se realizó un estudio retrospectivo, no aleatorio, realizado en una clínica privada de Lima, Perú. Se obtuvo la información de la historia clínica digital. Se incluyó a pacientes con el diagnóstico de infección por HP por biopsia y/o test rápido de la ureasa, obtenidos al realizar una endoscopía entre enero 2017 a octubre 2022. Debían haber recibido el tratamiento cuádruple en estudio o un esquema triple alternativo con amoxicilina, levofloxacino e inhibidor de bomba de protones y tener una prueba de aliento para HP en el lapso de 1 a 6 meses después del tratamiento. El esquema cuádruple con furazolidona logró la erradicación en 117/122 casos (95,9%) mientras que el triple con levofloxacino en 5/16 (31,2%) cuando se usó por 7 dias y en 22/38 (57,9%) cuando se usó por 10 días, siendo las diferencias altamente significativas (p>0,001). En conclusión, el tratamiento cuádruple con furazolidona mostró alta efectividad, mientras que el triple con levofloxacino no alcanzó niveles aceptables.
Our objective is to determine the effectiveness of a therapeutic regimen for helicobacter pylori that includes a proton pump inhibitor, doxycycline, furazolidone and bismuth in our location. We carried out a retrospective study, non-randomized, in a private hospital in Lima, Peru. Patients with biopsy and/or rapid urease test proven helicobacter pylori infection after an endoscopy, from January 2017 to October 2022 were included. They received the therapeutic regimen of the study or an alternative triple regimen with a proton pump inhibitor, amoxicillin and levofloxacin and were followed with a urea breath test within 1 to 6 months upon completion of therapy. The quadruple therapy with furazolidone obtained success in 117/122 cases (95.9%) while the triple therapy with levofloxacin only in 5/16 (31.2%) when used for 7 days and 22/38 (57.9%) when used for 10 days, a statistically significant difference with p<0.001. Conclusion: Quadruple therapy with furazolidone reached high effectiveness in our location, while triple therapy with levofloxacin was not an acceptable alternative.
RESUMEN
OBJECTIVE: To determine the effectiveness of two new therapeutic regimes for Helicobacter pylori versus triple therapy that includes a proton pump inhibitor, amoxicillin and clarithromycin. MATERIALS AND METHODS: prospective study, non-randomized, in a private Hospital in Lima, Peru. Patients with biopsy and/or rapid ureasa test proven Helicobacter pylori infection received one of the three therapeutic regimens and were followed with a urea breath test 1 to 6 months upon completion of therapy. RESULTS: Triple therapy achieved eradication in 49/68 of cases (71.2%); quadruple therapy (doxycycline + metronidazole + bismuth + esomeprazole) in 52/62 (83.9%), and the simplified regimen with doxycycline + furazolidone + bismuth, obtained success in 79/83 of cases (95.2%). Statistically significant difference with p<0.005 and p<0.05 respectively. CONCLUSION: Triple therapy against Hp does not achieve acceptable effectiveness in our institution. This highlights the need to look for new therapeutic options, being the simplified regime (doxycycline, furazolidone and bismuth) used in the current study a good option, requiring further studies for validation.
Asunto(s)
Antiácidos/uso terapéutico , Antibacterianos/uso terapéutico , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Inhibidores de la Bomba de Protones/uso terapéutico , Adolescente , Adulto , Anciano , Amoxicilina/uso terapéutico , Bismuto/uso terapéutico , Pruebas Respiratorias , Claritromicina/uso terapéutico , Doxiciclina/uso terapéutico , Quimioterapia Combinada , Femenino , Infecciones por Helicobacter/diagnóstico , Helicobacter pylori/aislamiento & purificación , Humanos , Masculino , Metronidazol/uso terapéutico , Persona de Mediana Edad , Perú , Estudios Prospectivos , Resultado del Tratamiento , Adulto JovenRESUMEN
RESUMEN Objetivo: Determinar la efectividad de dos nuevos esquemas para el tratamiento de Helicobacter pylori frente al esquema triple convencional de amoxilina, claritromicina y un inhibidor de bomba de protones. Materiales y métodos: Estudio prospectivo, no aleatorio, realizado en una clínica privada de Lima, Perú. Los pacientes con infección por Helicobacter demostrada por endoscopia con biopsia y/o test de la ureasa, recibieron uno de tres tratamientos en estudio y fueron examinados mediante el test del aliento con urea C14, entre 1 y 6 meses después. Resultados: El tratamiento triple convencional solo logró la erradicación en 49/68 casos (71,2%) y el cuádruple con doxiciclina, metronidazol, bismuto y esomeprazol lo hizo en 52/62 casos (83,9%) siendo esta diferencia no significativa (p>0,1). El esquema simplificado de doxiciclina, furazolidona y bismuto logró curar a 79/83 pacientes (95,2%) superando a los dos anteriores con valor significativo (p<0,005 y p<0,05 respectivamente). Conclusiones: El tratamiento triple convencional para Helicobacter no está alcanzando niveles aceptables de efectividad en nuestra institución. Esto enfatiza la necesidad de buscar nuevas alternativas; por lo que sería útil validar con nuevos estudios los buenos resultados logrados por el régimen Simplificado de doxiciclina, furazolidona y bismuto que aquí presentamos
ABSTRACT Objective: To determine the effectiveness of two new therapeutic regimes for Helicobacter pylori versus triple therapy that includes a proton pump inhibitor, amoxicillin and clarithromycin. Materials and methods: prospective study, non-randomized, in a private Hospital in Lima, Peru. Patients with biopsy and/or rapid ureasa test proven Helicobacter pylori infection received one of the three therapeutic regimens and were followed with a urea breath test 1 to 6 months upon completion of therapy. Results: Triple therapy achieved eradication in 49/68 of cases (71.2%); quadruple therapy (doxycycline + metronidazole + bismuth + esomeprazole) in 52/62 (83.9%), and the simplified regimen with doxycycline + furazolidone + bismuth, obtained success in 79/83 of cases (95.2%). Statistically significant difference with p<0.005 and p<0.05 respectively. Conclusion: Triple therapy against Hp does not achieve acceptable effectiveness in our institution. This highlights the need to look for new therapeutic options, being the simplified regime (doxycycline, furazolidone and bismuth) used in the current study a good option, requiring further studies for validation.
Asunto(s)
Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Helicobacter pylori , Infecciones por Helicobacter/tratamiento farmacológico , Inhibidores de la Bomba de Protones/uso terapéutico , Antiácidos/uso terapéutico , Antibacterianos/uso terapéutico , Perú , Bismuto/uso terapéutico , Pruebas Respiratorias , Estudios Prospectivos , Helicobacter pylori/aislamiento & purificación , Infecciones por Helicobacter/diagnóstico , Resultado del Tratamiento , Claritromicina/uso terapéutico , Doxiciclina/uso terapéutico , Quimioterapia Combinada , Amoxicilina/uso terapéutico , Metronidazol/uso terapéuticoRESUMEN
INTRODUCTION: It is important to detect and remove adenomas in order to prevent colon cancer. Angiogenesis is an early change in the pre malignant transformation sequence and narrow band imaging (NBI) allows for better visualization of the capillary pattern of the mucosa. OBJECTIVE: We present our data regarding the assessment of superficial lesions of the colon on colonoscopies using NBI as well as the Sano-Emura classification. MATERIALS & METHODS: Prospective study done in Lima Peru. Three endoscopists evaluate the capillary pattern of colonic lesions in real time using NBI and electronic magnification. These findings are then compared to the pathology report. RESULTS: 380 patients were evaluated with a total of 739 lesions; 473 adenomas, 241 non neoplastic lesions, and 25 serrated lesions. These were grouped depending on their NBI capillary pattern into two groups: Neoplastic (Sano-Emura types II, IIIa, and IIIb), and Non-Neoplastic (Sano-Emura type I). Sensitivity for adenomas 84%, diagnostic accuracy 77%, PPV 82%, NPV 67%, specificity 63%. Sensitivity and diagnostic accuracy improved to 94% and 84%, respectively when evaluating lesions of 5 mm to 9 mm. For diminutive rectosigmoid polyps, the NPV for adenomas was 81%. The serrated lesions showed both types of capillary pattern with equal frequency. CONCLUSIONS: Our results using NBI with electronic magnification showed that this method is useful for the differentiation of lesions 5 mm or bigger, as reported previously. Accuracy was diminished when evaluating lesions less than 5 mm. NBI was not capable of aiding in the differential diagnosis of serrated lesions.
Asunto(s)
Adenoma/diagnóstico , Capilares/patología , Colon/irrigación sanguínea , Neoplasias del Colon/diagnóstico , Colonoscopía/métodos , Mucosa Intestinal/irrigación sanguínea , Imagen de Banda Estrecha/métodos , Colon/patología , Femenino , Humanos , Mucosa Intestinal/patología , Masculino , Persona de Mediana Edad , Perú , Sector Privado , Estudios Prospectivos , Sensibilidad y EspecificidadRESUMEN
INTRODUCCION: La detección y resección de los adenomas es importante para prevenir el cáncer colorrectal. La angiogénesis es un factor primordial en el crecimiento tumoral y la endoscopía con imagen de banda estrecha (NBI) permite una mejor evaluación del patrón capilar de la mucosa. OBJETIVO: Presentar nuestra experiencia en la diferenciación de las lesiones superficiales del colon, utilizando colonoscopía con NBI y la clasificación de Sano û Emura. MATERIAL & MÉTODOS: Estudio prospectivo realizado en Lima, Perú. Tres endoscopistas evalúan en tiempo real el patrón capilar de las lesiones, usando NBI con magnificación electrónica, y sus diagnósticos se correlacionan con el resultado histopatológico. RESULTADOS: se incluyen 380 pacientes con 739 lesiones; 473 adenomas, 241 pólipos no neoplásicos y 25 lesiones aserradas. Son divididas, por su patrón capilar al NBI, en dos grupos: Neoplásicas (Sano -Emura tipo II, IIIa y IIIb) y No Neoplásicas (Sano-Emura tipo I). Sensibilidad para adenomas: 84%, precisión diagnóstica: 77%, VPP: 82%, VPN: 67% y especificidad: 63%. La sensibilidad y la precisión diagnóstica aumentan a 94% y 84% en lesiones de 5 a 9 mm. En lesiones diminutas del recto-sigmoides, el VPN para adenomas mejora a 81%. Para las lesiones aserradas estos índices solo alcanzan el 50%. CONCLUSIONES: El NBI con magnificación electrónica resultó útil en la diferenciación de las lesiones de 5 mm o mayores, con resultados similares a estudios publicados. En lesiones menores de 5mm disminuyó la exactitud. Las lesiones aserradas no pudieron ser diferenciadas con NBI.
INTRODUCTION: It is important to detect and remove adenomas in order to prevent colon cancer. Angiogenesis is an early change in the pre malignant transformation sequence and narrow band imaging (NBI) allows for better visualization of the capillary pattern of the mucosa. OBJECTIVE: We present our data regarding the assessment of superficial lesions of the colon on colonoscopies using NBI as well as the Sano-Emura classification. MATERIALS & METHODS: Prospective study done in Lima Peru. Three endoscopists evaluate the capillary pattern of colonic lesions in real time using NBI and electronic magnification. These findings are then compared to the pathology report. RESULTS: 380 patients were evaluated with a total of 739 lesions; 473 adenomas, 241 non neoplastic lesions, and 25 serrated lesions. These were grouped depending on their NBI capillary pattern into two groups: Neoplastic (Sano-Emura types II, IIIa, and IIIb), and Non-Neoplastic (Sano-Emura type I). Sensitivity for adenomas 84%, diagnostic accuracy 77%, PPV 82%, NPV 67%, specificity 63%. Sensitivity and diagnostic accuracy improved to 94% and 84%, respectively when evaluating lesions of 5mm to 9mm. For diminutive rectosigmoid polyps, the NPV for adenomas was 81%. The serrated lesions showed both types of capillary pattern with equal frequency. CONCLUSIONS: Our results using NBI with electronic magnification showed that this method is useful for the differentiation of lesions 5 mm or bigger, as reported previously. Accuracy was diminished when evaluating lesions less than 5mm. NBI was not capable of aiding in the differential diagnosis of serrated lesions.